← Leaderboards
Donald I Abrams
University Of California San Francisco
$10,076,278
Attributed
$10,076,278
Total exposure
11
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–07$2M$1.5M$1M$500K$0
'05
'06
'07
Funding mix
By agency
NIH$10,076,278 · 11
By mechanism
U01$7,486,136 · 1
R01$1,012,986 · 2
M01$930,209 · 6
R21$646,947 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Donald Abrams$1,128
- Christian Vaisse$17,114,063
- Laurence H. Tecott$8,080,377
- Morris Schambelan$4,926,809
- Thomas Sterling Scanlan$10,376,751
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationAids TherapyAlternative MedicineHiv InfectionsAntiaids AgentPatient Oriented ResearchAids /Hiv DiagnosisHuman Immunodeficiency Virus 1Body CompositionCommunity Health ServicesCooperative StudyDehydroepiandrosteronePlacebosChemopreventionPrognosisAidsLongitudinal Human StudyCannabisOpportunistic InfectionsTherapy ComplianceVirus Replication
Grant awards (25)
Opioid and Cannabinoid Pharmacokinetic Interactions$181,569
R21 · FY2007 · DA · contact PI
COMMUNITY CONSORTIUM (CPCRA)$699,921
U01 · FY2006 · AI · contact PI
Opioid and Cannabinoid Pharmacokinetic Interactions$155,550
R21 · FY2006 · DA · contact PI
COMMUNITY CONSORTIUM (CPCRA)$1,139,647
U01 · FY2005 · AI
EFFECT OF MARIJUANA ON HIV-RELATED NEUROPATHIC PAIN$390,395
M01 · FY2005 · RR
VAPORIZATION AS A SMOKELESS CANNABIS DELIVERY SYSTEM$106,885
M01 · FY2005 · RR
ANTIHYPERLIPIDEMIC EFFECTS OF OYSTER MUSHROOMS IN HIV PATIENTS TAKING KALETRA$38,660
M01 · FY2005 · RR
MARIJUANA AND OPIOIDS FOR TREATING CANCER PAIN$4,078
M01 · FY2005 · RR
COMMUNITY CONSORTIUM (CPCRA)$989,647
U01 · FY2004 · AI
EFFECT OF MARIJUANA ON HIV-RELATED NEUROPATHIC PAIN$220,117
M01 · FY2004 · RR
Antihyperlipidemic Effects of Oyster Mushrooms$154,914
R21 · FY2004 · AT
Effect of marijuana on neuropathic pain in HIV-related peripheral neuropathy$94,921
M01 · FY2004 · RR
DHEA effects on HIV-1 replication and host immunity$71,190
M01 · FY2004 · RR
MARIJUANA AND OPIOIDS FOR TREATING CANCER PAIN$3,963
M01 · FY2004 · RR
COMMUNITY CONSORTIUM (CPCRA)$1,139,647
U01 · FY2003 · AI
Antihyperlipidemic Effects of Oyster Mushrooms$154,914
R21 · FY2003 · AT
COMMUNITY CONSORTIUM (CPCRA)$1,108,877
U01 · FY2002 · AI
Dehydroepiandrosterone Effects on HIV-1 Replication$319,388
R01 · FY2002 · AT
COMMUNITY CONSORTIUM (CPCRA)$1,079,003
U01 · FY2001 · AI
Dehydroepiandrosterone Effects on HIV-1 Replication$310,977
R01 · FY2001 · AT
Dehydroepiandrosterone Effects on HIV-1 Replication$23,000
R01 · FY2001 · AT
COMMUNITY CONSORTIUM (CPCRA)$952,983
U01 · FY2000 · AI
COMMUNITY CONSORTIUM$376,411
U01 · FY2000 · AI
Dehydroepiandrosterone Effects on HIV-1 Replication$309,314
R01 · FY2000 · AT
SHORT TERM EFFECTS OF CANNABIONOIDS IN HIV PATIENTS$50,307
R01 · FY2000 · DA